LEGN logo

LEGN
Legend Biotech

1,134
Mkt Cap
$5.2B
Volume
1.05M
52W High
$45.30
52W Low
$16.24
PE Ratio
-20.58
LEGN Fundamentals
Price
$29.57
Prev Close
$27.99
Open
$27.62
50D MA
$22.20
Beta
0.55
Avg. Volume
2.3M
EPS (Annual)
-$1.61
P/B
5.37
Rev/Employee
$355,731.44
$3,472.23
Loading...
Loading...
News
all
press releases
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.read...
News Placeholder
More News
News Placeholder
Legend Biotech Q1 Earnings Call Highlights
Legend Biotech Q1 Earnings Call Highlights...
News Placeholder
Legend Biotech (LEGN) Projected to Post Earnings on Tuesday
Legend Biotech (NASDAQ:LEGN) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
News Placeholder
Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Legend Biotech Corporation Sponsored ADR $LEGN
Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 89.4% in the fourth quarter, according to the company in its most...
News Placeholder
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the...
News Placeholder
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC
Matthews International Capital Management LLC reduced its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 7.0% during the 4th quarter, according to its most recent...
News Placeholder
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
News Placeholder
HC Wainwright Reaffirms "Buy" Rating for Legend Biotech (NASDAQ:LEGN)
HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Legend Biotech in a report on Tuesday...
News Placeholder
Why Legend Biotech Stock Crushed the Market on Monday
Key PointsThis followed a sizable acquisition of a peer biotech by a pharmaceutical sector giant...
News Placeholder
LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?
After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available